From: Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months
Antibody
15 μg MSP3
30 μg MSP3
Engerix B
N
n
%
Total IgG
15
4
26.7
12
33.3
13
1
7.7
IgG1
100
10
83.3
2
15.4
IgG2
0
IgG3
86.7
11
91.7
6
46.2
IgG4
3
20